Home / Resources / ‘Faster, Better, More Efficient’ – Why Bayer Is Investing in ‘Precision Health’

‘Faster, Better, More Efficient’ – Why Bayer Is Investing in ‘Precision Health’

Article
Commercial
HBW-Insights-articles_hero

Like other big global OTC players, Bayer Consumer Health is stepping up its investment in digital self-care. In the first part of an exclusive two-part interview, HBW Insight interviews the company's head of R&D and chief scientific officer David Evendon-Challis to dig deeper into the rationale for setting up a new 'precision health' business unit.

There are predictions that precision health will be up to 20% of the consumer health market.
Bayer Consumer Health’s head of R&D and chief scientific officer David Evendon-Challis
Related products
Collection of consumer health products that HBW Insight provides news and insights about.
HBW Insight
The single source of news and insight for the health, beauty and wellness sectors
Patient using a medical device to check for blood sugar level.
Medtech Insight
The latest high-value news, analysis and strategic insights on the global medical technology sector
Collage of the various Pharma Ignite marketing capabilities supporting the whole product life cycle.
Pharma Ignite
A broad range of marketing services connecting clients with pharmaceutical industry stakeholders

Related resources

Biopharma professional on laptop browsing Pink Sheet for global policy and regulatory insights.
MAY 01, 2022
eBook
Regulatory & Compliance

Your Keys to Understanding EU Transparency

A collection of Pink Sheet articles covering evolving EU regulations on clinical trial disclosure and transparency

HBW-Insights-articles_resource-card-thumbnail
JUL 04, 2023
Article
Commercial

Bayer Consumer Health Exec Cites the ‘Huge Potential’ of OTC Digital Therapeutics, AI

Bayer Consumer Health's R&D head/chief scientific officer cites the opportunities in a new generation of OTC digital therapeutics and AI-driven self-care.

View All Resources